Treating Myeloproliferative Neoplasms (MPNs)

2 Views

07/29/23

Ellen Ritchie, MD, Associate Professor of Clinical Medicine, Weill Cornell Medical College, discusses the challenges of treating Myeloproliferative Neoplasms (MPNs).

MPNs are rare, chronic blood cancers. Chronic conditions last for a long period of time and may never go away. MPNs can be classified based on the presence or absence of a chromosomal abnormality called the Philadelphia chromosome. There are several types of Philadelphia chromosome–negative MPNs, which are:

- Polycythemia vera (PV)
- Essential thrombocythemia (ET)
- Myelofibrosis (MF)

Each type of MPN is characterized by a particular pattern of abnormal blood cell production that usually impacts one blood cell type more than the others. MPNs are progressive conditions, meaning that they worsen over time.

MPNs can affect people at any age, but they are more common in older adults.Mutations, or changes in certain genes, are thought to be a major cause of what are known as Philadelphia chromosome–negative MPNs, or "classical" MPNs. Even people who do not have these mutations may have MPNs.